新制癌菌素与单克隆抗体A7的嵌合Fab片段偶联物在携带人胰腺癌异种移植物的裸鼠中的生物分布。
Biodistribution of neocarzinostatin conjugated to chimeric Fab fragments of the monoclonal antibody A7 in nude mice bearing human pancreatic cancer xenografts.
作者信息
Otsuji E, Yamaguchi T, Yamaoka N, Taniguchi K, Kato M, Kotani T, Kitamura K, Takahashi T
机构信息
First Department of Surgery, Kyoto Prefectural University of Medicine.
出版信息
Jpn J Cancer Res. 1994 May;85(5):530-5. doi: 10.1111/j.1349-7006.1994.tb02391.x.
In this study, we conjugated chimeric Fab fragments of the monoclonal antibody (MAb) A7, which reacts with pancreatic cancers, to the antitumor drug neocarzinostatin (chA7Fab-NCS) and intravenously injected 125I-labeled chA7Fab-NCS into nude mice bearing a human pancreatic cancer xenograft. We compared the tumor localization of 125I-labeled chA7Fab-NCS with that of conventional 125I-labeled A7-NCS, which was produced by conjugation of MAb A7 and NCS. 125I-Labeled chA7Fab-NCS accumulated in the tumor earlier than 125I-labeled A7-NCS, and significantly larger amounts of 125I-labeled chA7Fab-NCS had accumulated in the tumor 1 hour after injection. The results suggest that chA7Fab may be a suitable carrier for NCS in immunotargeting therapy against pancreatic cancer.
在本研究中，我们将与胰腺癌发生反应的单克隆抗体（MAb）A7的嵌合Fab片段与抗肿瘤药物新制癌菌素（chA7Fab-NCS）偶联，并将125I标记的chA7Fab-NCS静脉注射到携带人胰腺癌异种移植瘤的裸鼠体内。我们将125I标记的chA7Fab-NCS的肿瘤定位与通过MAb A7和NCS偶联产生的传统125I标记的A7-NCS的肿瘤定位进行了比较。125I标记的chA7Fab-NCS比125I标记的A7-NCS更早地在肿瘤中蓄积，并且在注射后1小时，大量的125I标记的chA7Fab-NCS已在肿瘤中蓄积。结果表明，chA7Fab可能是新制癌菌素在胰腺癌免疫靶向治疗中合适的载体。
Zotero 插件